Physician profile
Marcos Rothstein
NPI 1285650507
$349,985.06
in general payments reported to CMS, 2019-2025
19 companies · $34K in 2025
The $34K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190K · 2020: $34K · 2021: $9,503 · 2022: $18K · 2023: $33K · 2024: $32K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $75K · Travel and Lodging: $11K · Education: $10K · Food and Beverage: $3,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $75,220.00 |
| Travel and Lodging | $10,736.59 |
| Education | $10,236.87 |
| Food and Beverage | $3,300.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $123,966.17 | 2019-2025 | Renal - Pd, Renal - Acute |
| Amgen INC. | $93,591.97 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $53,957.01 | 2019-2020 | |
| Vantive US Healthcare LLC | $32,113.88 | 2025 | Renal - Pd |
| Rockwell Medical, INC. | $21,855.93 | 2019-2020 | |
| Vifor Pharma, INC. | $13,340.67 | 2019-2025 | Korsuva, Veltassa |
| Daiichi Sankyo INC. | $9,738.76 | 2019 | |
| Travere Therapeutics, INC. | $369.43 | 2024-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $249.81 | 2021 | |
| Cvrx, INC. | $182.99 | 2021 | |
| Calliditas Therapeutics US INC. | $127.69 | 2023 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $121.81 | 2023 | |
| Opko Pharmaceuticals, LLC | $120.47 | 2019 | |
| Mallinckrodt Enterprises LLC | $76.99 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.27 | 2024 | Wegovy |
| Nxstage Medical, INC. | $30.10 | 2019 | |
| Boston Scientific Corporation | $29.06 | 2025 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcos Rothstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.